Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Must-Have Cooking Machine in Your Kitchen - 2What is a Trump Gold Card? U.S. launches $1 million immigration visas
- 3Mossad unveils network of Hamas terror infrastructure across Europe
- 4Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- 51st results from Blue Ghost lunar lander reveal how much we still don't know about the moon
- Poll: Most are satisfied with their health insurance, but a quarter report denials or delays
- South Africa collects record $117B tax haul
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- Ice Spice's 'Big Guy' SpongeBob song is stuck in everyone's heads again — and TikTok is fueling it
- New Cheetos and Doritos will be free of artificial dyes
- The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- REWE launches seventh Pick&Go test store in Hanover
